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Among Epstein-Barr virus (EBV)-associated neoplasms, EBV-
associated gastric carcinoma (EBVaGC) is the most common 
tumor worldwide. In contrast to the predominant site of oc-
currence of EBV-negative gastric carcinoma in the antrum, 
EBVaGC occurs most frequently in the proximal stomach, 
including the cardia, fundus and body. Microscopically, EB-
VaGC can be subclassified into three histological subtypes 
according to the host cellular immune responses: lymphoepi-
thelioma-like carcinoma, carcinoma with Crohn’s disease-like 
lymphoid reaction, and conventional-type adenocarcinoma. 
Recent studies have shown that patients with the lympho-
epithelioma-like carcinoma subtype of EBVaGC have the 
best overall and disease-free survival, followed by Crohn’s 
disease-like reactions, which in turn have better survival than 
patients with conventional-type adenocarcinoma. Histologic 
subclassiﬁ  cations of EBVaGCs are based on the differing de-
gree and pattern of inﬂ  ammatory response and the extent of 
desmoplasia. Because these subclassiﬁ  cations appear to be 
a powerful prognostic parameter, further research into the 
underlying mechanisms of the cellular immune reaction in 
these pathologic subtypes of EBVaGCs may play a key role in 
understanding the innate immune response of patients with 
this highly aggressive carcinoma. (Gut Liver 2011;5:143-
148)
Key Words: Epstein-Barr Virus; Stomach; Carcinoma; Pathol-
ogy; Prognosis
INTRODUCTION
Epstein-Barr virus (EBV) is a ubiquitous γ-1 herpes virus usu-
ally acquired during childhood via salivary transmission, which 
establishes a life-long persistent infection of B cells in over 90% 
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of adults.
1 EBV infection is implicated in the etiology of B and 
T lymphomas, NK cell malignancies, nasopharyngeal undif-
ferentiated carcinomas and a subset of smooth muscle tumors.
2 
EBV-associated gastric carcinoma (EBVaGC) is defined by the 
presence of EBV in gastric tumor cells by EBV-encoded RNA 
(EBER) in situ hybridization and constitutes about 8.7% of all 
GC,
3 ranging between 1.3% to 20.1% (or 2% to 18%).
4-6 Among 
EBV-associated neoplasms, EBVaGC is most common and dis-
tributed worldwide, while Burkitt’s lymphoma and nasopharyn-
geal carcinoma are endemic to equatorial Africa and southeast 
China, respectively. 
Lymphoepithelioma-like carcinoma (LELC) is a relatively rare 
type of GC, which constitutes approximately 1% to 4% of all 
GCs and is highly associated with EBV infection.
7-9 The preva-
lence of EBVaGC among LELC of the stomach is over 90%,
3 and 
more than 80% of LELCs have been found to be EBV-associat-
ed.
10 
It is now widely accepted that LELC of the stomach is as-
sociated with a significantly better prognosis. However, some 
studies have shown that EBVaGCs do not differ in the prognosis 
compared to their EBV-negative counterparts.
11-13 This discrep-
ancy in prognosis may be associated with diverse pathologic 
features of EBVaGC. Conventional histologic types of GC other 
than LELC also are associated with EBV in about 10% to 20% 
of all GCs.
3,14 In the current article, we reviewed the relationship 
between pathologic features, especially host cellular immune 
responses and prognosis in EBVaGC. 
CLINICAL FEATURES OF EBV-ASSOCIATED GASTRIC 
CARCINOMA
The clinicopathologic features of EBVaGC observed in meta-
analyses are described in Table 1. Although some have dem-
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.144  Gut and Liver, Vol. 5, No. 2, June 2011
onstrated that EBVaGC occur more frequently in male and in 
younger age group, most studies showed no evident age de-
pendence of EBVaGC.
3,6 In our Korean cohorts, although male 
affected more frequently than female patients, we failed to 
demonstrate any age preference.
11,14 Moreover, although lymph 
node metastasis was significantly frequent in EBVaGCs com-
pared to EBV-negative GCs, there was no significant difference 
in the depth of invasion or clinical stage between EBVaGC and 
EBV-negative GC.
6 Although the numbers of patients with pT3-
4 stages were relatively smaller than control group, Song et al.
14 
showed that EBVaGCs are associated with lower pT stages, pN 
stages and International Union Against Cancer/American Joint 
Committee on Cancer (UICC/AJCC) stages than control patients. 
Most studies did not show any relationship between EBV 
presence and GC prognosis.
15 Koriyama et al.
16 first demon-
strated that EBV was related to poor prognosis in intestinal-
type carcinoma, whereas the diffuse-type EBVaGC had better 
prognosis even when LELC were excluded. This study is the 
first demonstrating the relationship between prognosis and 
histologic type of EBVaGCs. In our analyses with large number 
of EBVaGCs,
14 although patients with EBVaGC showed longer 
overall and disease-free survival than patients with EBV-nega-
tive GC by univariate analysis, multivariate analysis with Cox 
proportional hazards failed to show any significant difference in 
spite of their lower UICC/AJCC stages. However, stratification of 
EBV-associated GCs by host cellular immune responses showed 
that patients with LELC and LELC+CLR have significantly longer 
overall survival time and disease-free survival (Table 2).
14
From a clinical perspective, endoscopy is the most useful 
modality for the diagnosis of EBVaGC. Although distinguish-
ing endoscopic findings are not described, some have reported 
submucosal nodules of carcinoma with lymphoid stroma.
17,18 
In these circumstances, characteristic submucosal tumor-like 
protrusions without clear tumor margins are described. The sub-
mucosal mass lesion, one of the various appearances of LELC, 
can be misdiagnosed as submucosal tumors.
18 In these cases, 
endoscopic ultrasonography demonstrating hypoechoic sub-
mucosal mass (corresponding to lymphoid stroma composed of 
carcinoma cells and infiltrating lymphocytes) located in the hy-
perechoic submucosal layer of the gastric wall is useful distin-
guishing LELC from other submucosal tumors.
17,19 The authors 
have experienced small numbers of LELC cases mimicking sub-
mucosal tumor on endoscopic and radiologic findings. In these 
Table 1. The Clinicopathological Features of Epstein-Barr Virus 
(EBV)-Associated Gastric Carcinoma as Determined from a Meta-
Analysis
3,6
Clinicopathologic findings EBV-associated gastric carcinoma
Incidence 8.7% (1.3-20.1%)
Age More common in younger ages com-
pared to EBV-negative GC
Sex M>F
Geographic prevalence 9.9% from America, 8.3% for Asian, 
9.2% for European cases
Location of tumor in the 
stomach
Proximal stomach (cardia and body)
Depth of tumor invasion 10.5% of advanced GC (9.3% of T3 
and T4 GCs)
8.9% of early GC (10.0% of T1 and T2 
GCs) (p=0.70)
Lymph node metastasis 14.9% in GCs without lymph node 
metastasis
10.0% in GCs with lymph node me-
tastasis (p=0.03)
Clinical stage 8.5% of lower tumor stages
7.3% of higher tumor stages (p=0.31)
EBV positivity in LELC 86.4% of LELC
6.1% of non-LELC cases (p<0.001)
Gastric remnant carcinoma 14.0% of Billroth I patients
33.0% of Billroth II patients (p=0.04)
Helicobacter pylori infection 53.2% of EBVaGCs 
56.3% of EBV-negative GCs (p=0.40)
LELC, lymphoepithelioma-like carcinoma; EBVaGC, EBV-associated 
gastric carcinoma.
Table 2. Pathologic Features of Epstein-Barr Virus (EBV)-Associated 
Gastric Carcinoma
6,12,14,17,20,30
Macroscopic
  Location Proximal stomach (cardia and/or body)
  Shape Markedly increased ratio of thickness to width
  Numbers Often multiple
Microscopic
  Histologic subclassification
    LELC Well-defined tumor margin
More numbers of lymphocytes than the tumor cells 
Syncytial growth pattern with poorly formed landular 
structures
No desmoplasia
‘Lace pattern’ in intramucosal tumor
    CLR Three or more lymphoid follicles at the edge of the 
tumor
Smaller numbers of lymphocytes than tumor cells
Frequent tubule or gland formation
Minimal or no desmoplasia
    CA Rare lymphoid follicles (<3 per tissue section)
Prominent desmoplasia
  T stage No significant difference with EBV-negative GC
 (but tend to be more frequent in lower T stages)
  N stage More frequent in GCs without lymph node metastasis
  Survival No significant difference compared to EBV-negative GC
After histologic stratification, LELC>CLR>CA
LELC, lymphoepithelioma-like carcinoma; CLR, carcinoma with 
Crohn’s disease-like lymphoid reaction; CA, conventional adenocarci-
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cases, multiple deep biopsies usually confirmed the presence of 
carcinoma. Hence, during the endoscopic follow up of submu-
cosal tumors, when the endoscopists experience rapid increase 
of size or ulcer in spite of small sizes, multiple deep biopsies are 
requested to rule out the possibility of EBVaGCs.
PATHOLOGIC FEATURES OF EBV-ASSOCIATED GASTRIC 
CARCINOMAS
Table 2 describes macroscopic and microscopic features of 
EBVaGC.
1. Macroscopic ﬁ  ndings
EBVaGC develops most often in the proximal stomach, in-
cluding cardia, fundus and body, in contrast to the predomi-
nance of antrum in EBV-negative GC in the GC prevalent areas 
such as Korea. EBVaGC was detected in 11.8% of the cases in 
the cardia, in 13.0% in the body, and in 5.9% in the antrum, 
indicating that there is a significant relationship between the 
tumor location in the stomach and EBVaGC.
6 
Some have reported that macroscopic findings of advanced 
EBVaGC show markedly increased ratio of thickness to width 
compared to EBV-negative GC.
18-20 However, these observations 
were based on adopting only LELC and excluding other histo-
logic types of EBVaGC. If a certain EBVaGC is conventional-
type adenocarcinoma rather than LELC, it can show conven-
tional gross findings similar to EBV-negative counterparts.
There are scattered reports indicating that the incidence of 
multiple synchronous carcinomas appears to be higher in EB-
VaGC than in EBV-negative GC.
21,22 
2. Microscopic ﬁ  ndings 
EBVaGC can be divided into three histologic subtypes ac-
cording to microscopic findings based on host cellular immune 
responses.
14 A recent study on 123 EBVaGCs showed that 53 
(43.1%) was lymphoepithelioma-like carcinoma (LELC), 52 
(42.3%) was Crohn’s disease-like lymphocytic reaction (CLR), 
and 18 (14.6%) was conventional adenocarcinoma (CA).
14
1) Lymphoepithelioma-like carcinoma 
Typical microscopic findings of LELC are defined by 1) well-
defined tumor margin, 2) dense lymphocytic infiltration of a de-
gree whereby the number of tumor infiltrating lymphocytes was 
greater than the tumor cells throughout the tumor, 3) indistinct 
cytoplasmic borders and a syncytial growth pattern with poorly 
formed glandular structures, and 4) no desmoplasia (Fig. 1).
14 
Particularly, in the intramucosal stage, LELC shows a ‘lace pat-
tern’ which consists of the connection and fusion of neoplastic 
glands (Fig. 2).
23
Although many EBVaGCs show the pathologic findings 
similar to LELC, diagnosis of EBVaGC need for caution because 
many lymphocytes can infiltrate around tumor cells in other 
subtypes of EBVaGC and confirmation of EBV is prerequisite. 
So, strict criteria to diagnose LELC should be applied in order to 
subclassify EBVaGC and further validate their clinical signifi-
cances.
2) Carcinoma with Crohn’s disease-like lymphoid reaction 
Carcinoma with Crohn’s disease-like lymphoid reaction (CLR) 
was defined by 1) patchy lymphocytic infiltration with 3 or 
more lymphoid follicles with active germinal centers per tissue 
Fig. 1. (A) Lymphoepithelioma-like 
carcinoma with dense lymphocytic 
infiltration and a pushing margin. 
Lymphocytes outnumber tumor 
cells (H&E stain, ×4). (B) Photo-
micrograph of Epstein-Barr virus-
encoded RNA as determined by in 
situ hybridization (×4). Only tumor 
cell nuclei are positive for staining, 
whereas lymphocytes are negative.146  Gut and Liver, Vol. 5, No. 2, June 2011
section at the advancing edge of the tumor, 2) smaller numbers 
of lymphocytes than tumor cells, 3) frequent tubule or gland 
formation, and 4) minimal or no desmoplasia (Fig. 3). In this 
pathologic subtype, it is characteristic that desmoplastic reac-
tion is less prominent than conventional-type adenocarcinoma, 
especially of diffuse-type.
3) Conventional-type adenocarcinoma 
Carcinomas other than LELC or CLR can be classified as con-
ventional-type adenocarcinoma (CA). In contrast to extensive 
lymphocytic infiltrations found in LELC or CLR, CAs show scat-
tered lymphocytes infiltration with prominent desmoplasia and 
rarely forms lymphoid follicles with prominent germinal centers 
(Fig. 4). Sometimes, in the periphery of CAs, only 1 or 2 lym-
phoid aggregates per tissue section are observed. This subtype is 
least common among EBVaGCs and cannot be delineated histo-
logically from EBV-negative counterparts without confirmation 
of EBV within tumor cells.  
PROGNOSIS OF EBV-ASSOCIATED GASTRIC CARCINO-
MA IN RELATION TO PATHOLOGY
Among the three histologic subtypes described earlier, pa-
tients with LELC subtype of EBVaGC show the best overall and 
disease-free survival followed by CLR, which showed better 
survival than CA patients.
14 So this histologic subclassification 
of EBVaGC into 3 distinct subsets seems to be a powerful prog-
nostic parameter. 
In patients with GC, tumor infiltrating lymphocytes or den-
dritic cells have been associated with favorable prognosis.
24-26 
Several studies have reported that the infiltrating cells in EB-
VaGC are CD8+ T cells and mature dendritic cells.
27-29 Lympho-
cytic infiltration around tumor can be considered as a host im-
mune reaction against tumor cells, although the exact cellular 
Fig. 3. Carcinoma with Crohn’s disease-like lymphoid reaction (H&E 
stain, ×4). Well-formed lymphoid follicles are easily found, but the 
tumor margin is somewhat infiltrative and tumor cells outnumber 
lymphocytes.
Fig. 4. Conventional-type adenocarcinoma (H&E stain, ×4). Lympho-
cytic infiltration is rarely identified.
Fig. 2. (A) Tumor cells show a ‘lace pattern,’ the connection and fusion of neoplastic glands (H&E stain, ×10). (B) In situ hybridization for Epstein-
Barr virus-encoded RNA in early gastric carcinoma (×10). Song HJ, et al: EBV-Associated Gastric Carcinoma and Prognosis  147
characteristics or their roles are not certain at the present time. 
More dense lymphocytic infiltration could be considered as a 
stronger host immune reaction, and this assumption is well cor-
related with prognostic differences. 
Recent meta-analyses revealed that there was no significant 
association between EBVaGC and EBV-negative GC in the same 
tumor invasion depth (T stage) or lymph node metastasis (N 
stage).
6 Considering the prognostic significances of host cellular 
immune reaction, further studies are needed. Application of this 
type of histologic subclassification of EBVaGC, based mainly on 
host cellular immune response, may be helpful in predicting the 
prognosis of not only the patients with EBVaGC but also in the 
patients with other histological types of gastric cancer with neg-
ative EBV. Further elucidation of the underlying mechanisms of 
host cellular immune responses may guide the future develop-
ment of immunotherapy as a therapeutic strategy for patients 
with GC.
CONCLUSION AND FUTURE PERSPECTIVES
EBV in situ hybridization is not routinely performed in daily 
pathology practice in many hospitals worldwide. Therefore, it is 
important to identify the characteristic pathological features of 
EBVaGC. Furthermore, pathologic subclassification of EBVaGCs 
according to histology reflecting host immune responses against 
tumor is an important prognostic factor. It will also be helpful 
to develop simple and easily applicable immunohistochemical 
methods to detect the EBV in the fixed tissue sections. Further 
research on underlying mechanisms of cellular immune reac-
tion in EBVaGCs may play a key role in stimulating the innate 
immune response in patients with this highly aggressive carci-
noma.
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